Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease

NCT00601146 | Completed Results

• 1 other identifier: 06-122
• Study Type: interventional
• Target: 39
• Locations: 1 country
• Sites: 2

Brief Summary

This research study is being done because patients with a history of chest radiation treatment for Hodgkin's disease have been shown to be at increased risk for developing lung cancer a number of years out from treatment. The risk appears to be further increased among patients with a smoking history. Currently, the practice is to recommend annual low-dose chest CT scans in survivors of Hodgkin's disease who have received prior chest radiation treatment and who have at least a moderate smoking history. In this study, the CT scans will be read and interpreted by the study radiologist, and the results recorded in a consistent manner.

Conditions

Lung Cancer

Keywords

Hodgkin's disease; CT scan

Outcome Measures

Primary Outcomes (1)

• To Prospectively Collect Data on Chest CT Screening for Patients at Increase Lung-cancer Risk After Hodgkin's Disease.

  In this study, patients will under annual low-dose chest CT screening. The total number of lung cancer detected through the screening will be recorded

  3 years

Study Arms (1)

Low-dose Chest CT screening

EXPERIMENTAL

Annual low-dose Chest CT screening

Procedure: chest computed tomography scan

Interventions

chest computed tomography scan PROCEDURE

Once a year for three years

Also known as: CT scan

Low-dose Chest CT screening

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years or longer from initial Hodgkin's disease diagnosis
• Current age 18 or older
• Received mediastinal irradiation and/or alkylating-agent based chemotherapy
• Smoking history of 10-pack years or more, or current smoker
• Pre-approval from the participant's insurance company for the CT study

You may not qualify if:

• Patients with a history of lung cancer
• Currently receiving treatment for another cancer diagnosis
• Known diagnosis of any metastatic cancer
• Pregnant women

Sponsors & Collaborators

• Dana-Farber Cancer Institute: lead
• Brigham and Women's Hospital: collaborator

Study Sites (2)

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

Location

Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States

Location

MeSH Terms

Conditions

Lung Neoplasms; Hodgkin Disease

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Lymphoma; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Results Point of Contact

• Title: Andrea Ng
• Organization: DFCI

ang@lroc.harvard.edu

617-732-6310

Study Officials

• Andrea K. Ng, MD

  Dana-Farber Cancer Institute/Brigham and Women's Hospital

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Radiation Oncologist

Model Details: Single arm study of low-dose Chest CT screening for long-term Hodgkin lymphoma survivors

Study Record Dates

• First Submitted: January 15, 2008
• First Posted: January 25, 2008
• Study Start: November 1, 2006
• Primary Completion: December 1, 2010
• Study Completion: December 1, 2019
• Last Updated: January 21, 2020
• Results First Posted: February 17, 2016

Record last verified: 2020-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)